COVID-19 & Hematologic Malignancies: Episode 1 - Effective Management from New York to California

COVID-19 & Hematologic Malignancies: Episode 1 - Effective Management from New York to California

On-Demand Webcast
Moderator

Joseph R. Mikhael, MD, MEd, FRCPC
Professor, Applied Cancer Research and Drug Discovery 
City of Hope Cancer Center 
Translational Genomics Research Institute   
Phoenix, Arizona

Faculty

John P. Leonard, MD
Professor, Medicine
Center for Lymphoma and Myeloma 
Weill Cornell Medicine
New York, New York

Nina Shah, MD
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California 

Michael J. Satlin, MD
Assistant Professor 
Infectious Disease
Weill Cornell Medicine
New York, New York

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

Intended Learners

This activity is intended for clinicians who encounter patients with hematologic malignancies, including hematologists; hematologic, medical, radiation, and surgical oncologists; and other HCPs, such as pathologists, internists/hospitalists, infectious disease specialists, pulmonologists, critical care specialists, medical students, oncology nurses, NPs, PAs, pharmacists, phlebotomists, and clinical laboratory technologists working as part of the multidisciplinary oncology team during the COVID-19 pandemic.

Overview

The COVID-19 pandemic has placed an unprecedented burden on both patients and healthcare workers in the United States, and clinicians who must manage the treatment of hematologic malignancies in this crisis are facing numerous unique challenges. Older individuals, as well as those with underlying health conditions, including cancer, are more likely to develop major complications with COVID-19. Healthcare providers for these patients must therefore ensure the continuation of appropriate oncologic care while minimizing the risk of exposure to SARS-CoV-2, the causative virus of COVID-19, or the development of severe complications from COVID-19. Guidance is only just starting to emerge regarding stopping, delaying, or modifying treatment for hematologic malignancies. Further, recommendations regarding the prevention, diagnostic testing, and treatment of COVID-19 are continuously evolving. Thus, in this rapidly changing and uncertain environment, it is vitally important that information is provided to clinicians that will help them continue to deliver essential care to these patients.

This webcast is a roundtable discussion with experts in lymphoma, myeloma, and infectious disease that aims to fill the gaps surrounding challenges faced by US healthcare practitioners as they manage the treatment of patients with hematologic malignancies in the midst of the COVID-19 pandemic.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the epidemiology, pathology and current treatment strategies of COVID-19  
  2. Develop approaches to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies 
  3. Evaluate current COVID-19 treatment strategies for potential interactions with anticancer agents
  4. Identify, mitigate, and manage current and prospective diagnostic, therapeutic, and monitoring challenges in oncology care due to the reallocation of health resources as a result of the COVID-19 pandemic 
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by May 13, 2021. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: May 13, 2020
Expiration Date: May 13, 2021
Estimated Time to Complete: 1.0 hour

There is no fee associated with this activity.

Educational Support

This program was supported through educational grants from Bristol Myers Squibb, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer Inc. 

CONTINUING EDUCATION

 In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

NACCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACY

This enduring, knowledge-based activity (Universal Activity Number JA0006201-0000-20-110-H01-P) has been approved for a maximum of 1.00 contact hours (0.10 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 days after completion of the course. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at c.bolwell@imedex.com or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.

NURSING

This continuing nursing education activity awards 1.00 contact hours.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

PLANNING COMMITTEE

In addition to the faculty listed below, Imedex/NACCME planners and staff include: Chris Bolwell, Samantha Conforti, and Griselda Zuccarino-Catania, PhD.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Griselda Zuccarino-Catania, PhD discloses that her spouse is employed by Janssen Pharmaceuticals, Inc.

FACULTY

Joseph Mikhael, MD, MEd, FRCPC has served as a consultant for Amgen, Celgene Corporation, GlaxoSmithKline, Janssen Biotech, Karyopharm, Sanofi, and Takeda.

John P. Leonard, MD has served as a consultant for AstraZeneca, ADC Therapeutics, Bayer, BMS/Celgene, Epizyme, Gilead/Kite, Karyopharm, GenMab, MEI Pharma, Multenyi, Regeneron, and Sutro.

Nina Shah, MD has received research support from Celgene/BMS, Janssen, Bluebird Bio, Sutro BIopharma, Teneobio, and has served as a consultant for Genentech, Seattle Genetics, oncopeptides, Karyopharm, Surface Oncology, Precision Biosciences, GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, and Kite.

Michael J. Satlin, MD disclosed no relevant financial relationships with any commercial interests.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.